Tisagenlecleucel in Primary CNS Lymphoma
In this study, is researching the safety of tisagenlecleucel in participants with primary central nervous system lymphoma. .

-The name of the study intervention is tisagenlecleucel.
Primary CNS Lymphoma|Refractory Primary CNS Lymphoma|Relapsed Primary CNS Lymphoma
BIOLOGICAL: Tisagenlecleucel
Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE Criteriaand ASTCT 2018 (CRS/NT), 12 Months
Objective disease response to tisagenlecleucel, IPCG response criteria., 1 Month|Objective disease response to tisagenlecleucel, IPCG response criteria., 3 Months|Objective disease response to tisagenlecleucel, IPCG response criteria., 6 months|Objective disease response to tisagenlecleucel, IPCG response criteria., 12 months|Overall Survival Rate, Kaplan-Meier method, 15 years|Progression Free Survival Rate, Kaplan-Meier method, from the date of assignment until the date of first documented progression or date of deathfrom any cause, whichever comes first, assessed up to 100 months
This research study is a Pilot Study, which is the first time investigators are examining this intervention in people with primary central nervous system lymphoma.

* The name of the study intervention is tisagenlecleucel. Tisagenlecleucel is an investigational treatment that uses the participants own immune cells, called T cells, to try to kill the cancerous cells
* The research study procedures include screening for eligibility and study treatment including, leukapheresis, evaluations, and follow up visits.
* The study treatment will be one day and participants will be followed for up to 2 years.
* It is expected that about 6 people will take part in this research study